Clinical Policy: Etelcalcetide (Parsabiv)
Reference Number: CP.PHAR.379
Effective Date: 03.20.18
Last Review Date: 08.20
Line of Business: HIM, Medicaid

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
Etelcalcetide (Parsabiv®) is a calcium-sensing receptor agonist which binds to the calcium-sensing receptor (CaSR) on chief cells of the parathyroid gland.

FDA Approved Indication(s)
Parsabiv is indicated for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.

Limitation(s) of use: Parsabiv has not been studied in adult patients with parathyroid carcinoma, primary hyperparathyroidism, or with CKD who are not on hemodialysis and is not recommended for use in these populations.

Policy/Criteria
Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation® that Parsabiv is medically necessary when the following criteria are met:

I. Initial Approval Criteria
A. Secondary Hyperparathyroidism (must meet all):
   1. Diagnosis of secondary HPT associated with CKD;
   2. Prescribed by or in consultation with a nephrologist or endocrinologist;
   3. Age ≥ 18 years;
   4. Member is on hemodialysis;
   5. Lab results over the previous 3-6 months show trending increase in iPTH level or current (within the last 30 days) labs show iPTH above the normal levels;
   6. Failure of Sensipar® and a vitamin D analog (see Appendix B) at up to maximally indicated doses, unless clinically significant adverse effects are experienced or all are contraindicated;
      *Prior authorization may be required for Sensipar
   7. Member is not receiving other calcimimetics;
   8. At the time of request, member does not have serum calcium less than the lower limit of the normal range;
   9. Dose does not exceed 15 mg three times per week.
Approval duration: 6 months
B. Other diagnoses/indications
1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): HIM.PHAR.21 for health insurance marketplace and CP.PMN.53 for Medicaid.

II. Continued Therapy
A. Secondary Hyperparathyroidism (must meet all):
1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
2. Member is responding positively to therapy as evidenced by a decrease in iPTH;
3. Member is not receiving other calcimimetics;
4. If request is for a dose increase, new dose does not exceed 15 mg three times per week.

Approval duration: 12 months

B. Other diagnoses/indications (must meet 1 or 2):
1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.

Approval duration: Duration of request or 6 months (whichever is less); or
2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): HIM.PHAR.21 for health insurance marketplace and CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:
A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policy – HIM.PHAR.21 for health insurance marketplace and CP.PMN.53 for Medicaid or evidence of coverage documents.

IV. Appendices/General Information
Appendix A: Abbreviation/Acronym Key
CaSR: calcium-sensing receptor
CKD: chronic kidney disease
HPT: hyperparathyroidism
iPTH: intact parathyroid hormone
PTH: parathyroid hormone

Appendix B: Therapeutic Alternatives
This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Dosing Regimen</th>
<th>Dose Limit/Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>cinacalcet</td>
<td>30 mg PO QD; titrate as necessary no more frequently than every 2 to 4 weeks through sequential doses of 60 mg, 90 mg, 120 mg, and 180 mg PO QD</td>
<td>300 mg/day</td>
</tr>
</tbody>
</table>
## CLINICAL POLICY

### Etelcalcetide

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Dosing Regimen</th>
<th>Dose Limit/Maximum Dose</th>
</tr>
</thead>
</table>
| calcitriol (Rocaltrol®) | Oral: 0.25 mcg PO QD or QOD; may increase dose by 0.25 mcg/day at 4 to 8 week intervals  
IV: 1 to 2 mcg/day IV 3 times weekly on  
approximately every other day; may increase by 0.5  
to 1 mcg/dose at 2 to 4 week intervals | Oral: 1 mcg/day  
IV: 4 mcg/day |
| doxercalciferol (Hectorol®) | Oral: 10 mcg PO 3 times weekly at dialysis; increase dose as needed at 8 week intervals in 2.5 mcg  
increments if iPTH is not lowered by 50% and fails to  
reach the target range  
IV: 4 mcg IV bolus 3 times weekly at the end of  
dialysis, increase dose as needed at 8 week intervals  
by 1 to 2 mcg increments if iPTH is not lowered by  
50% and fails to reach the target range | Oral: 20 mcg  
times weekly  
IV: 18 mcg/week |
| paricalcitol (Zemplar®) | 1 mcg PO daily if baseline iPTH level is 500  
picog/mL or less; 2 mcg PO daily if baseline iPTH  
level is greater than 500 picog/mL; may titrate dose  
at 2 to 4 week intervals | 0.24 mcg/kg |

*Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only  
and generic (Brand name®) when the drug is available by both brand and generic.*

### Appendix C: Contraindications/Boxed Warnings
- Contraindication(s): known hypersensitivity to etelcalcetide or any of its excipients
- Boxed warning(s): none reported

### Appendix D: General Information
- Secondary hyperparathyroidism (HPT) is most commonly seen in patients with chronic kidney disease (CKD). These patients present with elevated levels of parathyroid hormone (PTH) and an enlarged parathyroid gland. Increased levels of PTH result from vitamin D deficiency, hypocalcemia and hyperphosphatemia; all attributed to kidney failure. Over time, as kidney function deteriorates, secondary HPT becomes more severe and may lead to abnormalities in bone mineralization and turnover and soft tissue and vascular calcifications.
- Parsabiv treats secondary HPT in patients with CKD who are on dialysis. The maintenance dose of Parsabiv is individualized and titrated based on PTH and corrected serum calcium response. The dose may be increased by 2.5-5 mg no more frequently than every 4 weeks. Serum calcium levels should be measured 1 week after initiation of therapy or dosage adjustment, and every 4 weeks thereafter for maintenance. Also, PTH should be measured 4 weeks after initiation of therapy or dose adjustment. In individuals with PTH levels below the target range, reduce the dose of Parsabiv or temporarily stop the therapy. Once PTH and serum calcium levels return to the target range, therapy will be initiated at a lower dose. Among individuals with a corrected serum calcium of at least 7.5 mg/dL but below target range and without symptoms of hypocalcemia, consider reducing the dose, temporarily stopping therapy, or adding on therapies to increase serum calcium. If therapy is stopped, reinitiate at a lower dose when PTH and serum calcium levels return to the target range.
calcium levels return to the target range. If the corrected serum calcium falls below 7.5 mg/dL, or if patient is experiencing symptomatic hypocalcaemia, stop the therapy and treat hypocalcaemia.

- Cinaalcalcet should be discontinued for at least 7 days prior to starting Parsabiv.
- If serum calcium falls below 7.5 mg/dL or if patient reports symptoms of hypocalcemia, therapy should be discontinued.

V. Dosage and Administration

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Secondary HPT</td>
<td>Initial: 5 mg IV bolus 3 times per week administered at the end of hemodialysis; adjust in 2.5 or 5 mg increments no more frequently than every 4 weeks to maintain target PTH levels and normal serum calcium levels.</td>
<td>15 mg three times per week</td>
</tr>
</tbody>
</table>

VI. Product Availability
Solution in a single-dose vial for injection: 2.5 mg/0.5 mL, 5 mg/mL, 10 mg/2mL

VII. References

Coding Implications
Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

<table>
<thead>
<tr>
<th>HCPSC Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>J0606</td>
<td>Injection, etelcalcetide, 0.1 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Reviews, Revisions, and Approvals</th>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Policy created</td>
<td>03.20.18</td>
<td>08.18</td>
</tr>
<tr>
<td>3Q 2019 annual review: added the requirement to the Continued Therapy section that Parsabiv not be used concomitantly with any other calcimimetic agents for consistency with the Initial Approval Criteria section; references reviewed and updated.</td>
<td>05.10.19</td>
<td>08.19</td>
</tr>
</tbody>
</table>
**Important Reminder**
This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.
Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note:
For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2018 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.